New targeted drug shows promise for Hard-to-Treat cancers
NCT ID NCT07359066
First seen Jan 27, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This study tests a new drug called SPR1020 in 210 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells while causing fewer side effects, especially to the blood. The goal is to find the safest and most effective dose and see if it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Tumor Hospital of Harbin Medical University
RECRUITINGHarbin, Heilongjiang, 150081, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.